VIVTEX
Vivtex is a pre-clinical drug development company that focuses on therapies for GI-related diseases using oral oligonucleotide therapeutics. Their company has a strategic partnership with pharmaceutical companies to co-develop oral drugs.
VIVTEX
Industry:
Biotechnology Health Care Medical Service Industry
Founded:
2018-08-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.vivtex.com
Total Employee:
1+
Status:
Active
Contact:
508-494-1291
Email Addresses:
[email protected]
Technology used in webpage:
Euro Fastly Hosted
Similar Organizations
Akcea Therapeutics
Akcea Therapeutics is a development and commercialization company focused on helping patients living with serious and rare diseases.
Alcea Therapeutics
Alcea Tx is a preclinical therapeutics company focused on treating airway inflammation through immune tolerance.
Catalight Foundation
Catalight Foundation provide services to people with disabilities and their families to support them across their care journey.
Merits Health Products, Inc.
Merits Health Products is driven to improve lives - every day, all over the world
RIBOMIC
R&D medicine based on their own platform for developing medicine
RxCelerate
RxCelerate delivers complete preclinical drug development programmes and project management for virtual and semi-virtual companies.
Tarsa Therapeutics
Tarsa Therapeutics develops an oral formulation of calcitonin for the treatment and prevention of postmenopausal osteoporosis.
True Grace Health
True Grace is a nutritional supplement company offering the health and well-being of future generations.
United States of Care
United States of Care is a new movement to ensure that everyone has access to quality, affordable health care regardless of health status.
Current Employees Featured
Founder
Key Employee Changes
| Date | New article |
|---|---|
| 2023-02-21 | Vivtex Announces Promotion of Maureen Deehan To Chief Executive Officer |
Official Site Inspections
http://www.vivtex.com
- Host name: 151.101.130.159
- IP address: 151.101.130.159
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Vivtex"
Home - Vivtex
We create next generation oral therapeutics by partnering with the leading Pharma and Biotech Companies. Through our robotic screening technology and AI capabilities we identify new oral …See details»
About Us - Vivtex
Dr. von Erlach co-founded Vivtex and joined as its Chief Scientific Officer when Vivtex was formed as a MIT spin-off in 2018. Prior to that he led the interdisciplinary efforts around gastrointestinal model systems for oral drug …See details»
Vivtex - Crunchbase Company Profile & Funding
Vivtex is a pre-clinical drug development company that focuses on therapies for GI-related diseases using oral oligonucleotide therapeutics. Their company has a strategic partnership with pharmaceutical companies to co-develop oral drugs.See details»
Vivtex Company Profile 2024: Valuation, Funding
Information on valuation, funding, cap tables, investors, and executives for Vivtex. Use the PitchBook Platform to explore the full profile.See details»
Vivtex - VentureRadar
Vivtex is a pre-clinical drug development company that launched as a MIT spin off in September 2018 with the mission to develop better and safer drugs by improving oral drug delivery.See details»
Programs - Vivtex
We use our technology to create custom drug delivery systems enabling these drugs to be given via the oral route. We have a rapidly growing number of industry partnerships with currently 6 …See details»
Vivtex - Contacts, Employees, Board Members, Advisors & Alumni
Vivtex is a pre-clinical drug development company that focuses on therapies for GI-related diseases using oral oligonucleotide therapeutics.See details»
Maureen Deehan - CEO at Vivtex - The Org
Dr. Deehan joined Vivtex in December 2022 as the Chief Business & Operating Officer and was promoted to Chief Executive Officer in February 2023. She is a PhD qualified biotechnology …See details»
James Wright - Chief Development Officer at Vivtex
Dr. Wright joined Vivtex as SVP of Drug Development in 2018. He oversees Vivtex’s drug development activities and strategy.See details»
Vivtex enters research collaboration with Astellas Pharma
Jan 23, 2024 · Vivtex Corporation (“Vivtex” or “the Company”), a biotech company aiming to transform the development of oral biologic therapies for major diseases, announces that it has entered a research collaboration with Astellas Pharma …See details»
Vivtex Enters Research Collaboration with Astellas Pharma - Yahoo …
Jan 23, 2024 · Vivtex Corporation (“Vivtex” or “the Company”), a biotech company aiming to transform the development of oral biologic therapies for major diseases, announces that it has …See details»
Vivtex and AI Proteins Enter Strategic R&D Collaboration to …
Jan 18, 2024 · Vivtex Corporation (“Vivtex”), a biotech company aiming to transform the development of oral biologic therapies for major diseases, and AI Proteins, Inc., a growing …See details»
Press Releases - Vivtex
Vivtex Corporation (“Vivtex” or “the Company”), a biotech company aiming to transform the development of oral biologic therapies for major diseases, announces that it has entered a …See details»
Vivtex Enters Research Collaboration With Astellas Pharma
Vivtex scientists demonstrated the ability and potential of the GI-ORIS platform to expedite the development of new orally available biologic drugs in a 2020 study published in Nature …See details»
Vivtex Enters Research Collaboration with Astellas Pharma
Jan 23, 2024 · Vivtex Corporation (“Vivtex” or “the Company”), a biotech company aiming to transform the development of oral biologic therapies for major diseases, announces that it has …See details»
Orbis Medicines and Vivtex Form Research & Exclusive Licensing ...
Collaboration will unite Vivtex’s best-in-class oral bioavailability screening with Orbis’ leading platform for the discovery and development of oral macrocyclesSee details»
News - Vivtex
Vivtex CEO, Maureen Deehan, presents Vivtex's achievements in oral biologics delivery at the 2024 MIT Health Science Forum in Cambridge, MA, where experts gather to share insights on …See details»
The Republic of Poland Signs its Country Programme Framework …
6 hours ago · HE Ms Marzena Czarnecka, Minister of Industry, and Mr Hua Liu, IAEA Deputy Director General and Head of the Department of Technical Cooperation, signed Poland’s …See details»
Technology - Vivtex
We can systematically identify the best possible drug candidate and delivery system to maximize oral bioavailability through our GI-ORIS™ robotic screening technology. Gastrointestinal …See details»
Publications - Vivtex
Shi, Y., Reker, D., Byrne, J.D. et al. Screening oral drugs for their interactions with the intestinal transportome via porcine tissue explants and machineSee details»